Literature DB >> 29296941

Immunotherapy for acute lymphoblastic leukemia: from famine to feast.

Kara L Davis1, Crystal L Mackall1,2.   

Abstract

Publisher's Note: This article has a companion Point by Jabbour and Kantarjian. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Entities:  

Year:  2016        PMID： 29296941      PMCID： PMC5737176          DOI： 10.1182/bloodadvances.2016000034

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  25 in total

1.  Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Authors:  Matthias Klinger; Christian Brandl; Gerhard Zugmaier; Youssef Hijazi; Ralf C Bargou; Max S Topp; Nicola Gökbuget; Svenja Neumann; Mariele Goebeler; Andreas Viardot; Matthias Stelljes; Monika Brüggemann; Dieter Hoelzer; Evelyn Degenhard; Dirk Nagorsen; Patrick A Baeuerle; Andreas Wolf; Peter Kufer
Journal:  Blood       Date:  2012-05-16       Impact factor: 22.113

2.  Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.

Authors:  Ahmad Rayes; Richard L McMasters; Maureen M O'Brien
Journal:  Pediatr Blood Cancer       Date:  2016-02-23       Impact factor: 3.167

3.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

4.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

5.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

7.  Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.

Authors:  Min Zhu; Benjamin Wu; Christian Brandl; Jessica Johnson; Andreas Wolf; Andrew Chow; Sameer Doshi
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

8.  Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Authors:  Patrick Schlegel; Peter Lang; Gerhard Zugmaier; Martin Ebinger; Hermann Kreyenberg; Kai-Erik Witte; Judith Feucht; Matthias Pfeiffer; Heiko-Manuel Teltschik; Christina Kyzirakos; Tobias Feuchtinger; Rupert Handgretinger
Journal:  Haematologica       Date:  2014-04-11       Impact factor: 9.941

9.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

10.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal:  N Engl J Med       Date:  2016-06-12       Impact factor: 91.245
View more
  4 in total

1.  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Authors:  Vinodh Pillai; Kavitha Muralidharan; Wenzhao Meng; Asen Bagashev; Derek A Oldridge; Jaclyn Rosenthal; John Van Arnam; Jos J Melenhorst; Diwakar Mohan; Amanda M DiNofia; Minjie Luo; Sindhu Cherian; Jonathan R Fromm; Gerald Wertheim; Andrei Thomas-Tikhonenko; Michele Paessler; Carl H June; Eline T Luning Prak; Vijay G Bhoj; Stephan A Grupp; Shannon L Maude; Susan R Rheingold
Journal:  Blood Adv       Date:  2019-11-26

2.  Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.

Authors:  Regina M Myers; Agne Taraseviciute; Seth M Steinberg; Adam J Lamble; Jennifer Sheppard; Bonnie Yates; Alexandra E Kovach; Brent Wood; Michael J Borowitz; Maryalice Stetler-Stevenson; Constance M Yuan; Vinodh Pillai; Toni Foley; Perry Chung; Lee Chen; Daniel W Lee; Colleen Annesley; Amanda DiNofia; Stephan A Grupp; Samuel John; Deepa Bhojwani; Patrick A Brown; Theodore W Laetsch; Lia Gore; Rebecca A Gardner; Susan R Rheingold; Michael A Pulsipher; Nirali N Shah
Journal:  J Clin Oncol       Date:  2021-11-12       Impact factor: 44.544

3.  Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.

Authors:  Ángel Ramírez-Fernández; Óscar Aguilar-Sopeña; Laura Díez-Alonso; Alejandro Segura-Tudela; Carmen Domínguez-Alonso; Pedro Roda-Navarro; Luis Álvarez-Vallina; Belén Blanco
Journal:  Oncoimmunology       Date:  2022-03-23       Impact factor: 8.110

Review 4.  Development of CAR T Cell Therapy in Children-A Comprehensive Overview.

Authors:  Michael Boettcher; Alexander Joechner; Ziduo Li; Sile Fiona Yang; Patrick Schlegel
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.